Prosight Management’s Terns Pharmaceuticals TERN Stock Holding History

Prosight Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-202,300	Closed	-$10.7M	–	46
2026 Q1	$10.7M	Buy	202,300 +107,300	+113%	+$4.41M	1.75%	19
2025 Q4	$3.84M	Buy	+95,000	New	+$2.2M	0.79%	28

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prosight Management's TERN Position: Q2 2026 in Review

Prosight Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 202,300 shares — an estimated $10.7M sold.

Prosight Management first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $10.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Prosight Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Prosight Management sold 202,300 Terns Pharmaceuticals shares in Q2 2026, an estimated $10.7M.
Prosight Management first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Prosight Management's Terns Pharmaceuticals position peaked at $10.7M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.